SuperworthIronwood Pharmaceuticals profit margin IRWD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 33.4%
- Operating margin, 12 months
- 60.1%
- Net margin on a year earlier
- +35.9 pts
- Peer median
- 11.2%
Over the twelve months to Jun 30, 2026, Ironwood Pharmaceuticals kept 33.4% of its revenue as net profit, with an operating margin of 60.1%.
The median for 10 large drugmakers of a similar size is 11.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.1% | 33.3% | n/a |
| FY2024 | 0.3% | 26.5% | n/a |
| FY2023 | n/a | n/a | n/a |
| FY2022 | 42.6% | 61.0% | n/a |
| FY2021 | n/a | 56.1% | n/a |
| FY2020 | 27.3% | 36.7% | 99.2% |
| FY2019 | 5.0% | 28.0% | 94.4% |
| FY2018 | −81.5% | −55.1% | 90.6% |
| FY2017 | −39.2% | −25.9% | 93.6% |
| FY2016 | −29.8% | −18.9% | n/a |
| FY2015 | −95.4% | −68.3% | 100.0% |
| FY2014 | n/a | n/a | 81.4% |
| FY2013 | n/a | n/a | 68.5% |
| FY2012 | −48.3% | −48.4% | n/a |
| FY2011 | −98.5% | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 33.4% | +35.9 pts | 60.1% | |
| Q1 FY26 | 28.3% | +38.4 pts | 55.4% | |
| Q4 FY25 | 8.1% | +7.9 pts | 33.3% | |
| Q3 FY25 | 8.4% | +9.1 pts | 36.3% | |
| Q2 FY25 | −2.6% | −4.9 pts | 23.8% | |
| Q1 FY25 | −10.2% | n/a | 16.7% | |
| Q4 FY24 | 0.3% | n/a | 26.5% | |
| Q3 FY24 | −0.7% | n/a | 26.2% | |
| Q2 FY24 | 2.3% | n/a | 28.4% | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| IRWDIronwood Pharmaceuticals | 33.4% |
| PBYIPuma Biotechnology | 11.6% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| ARVNArvinas | 2.9% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| Peer median | 11.2% |
Where Ironwood Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Ironwood Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.